Présentations UMR_S 1176 (ou impliquant des membres de l’UMRS1176) + présentations par un des membres du CRMW au congrès de l’ISTH à Toronto
Communications orales :
Peter Lenting: Factor VIII and VWF, rekindling a longstanding relationship
Session SSC Von Willebrand factor
Samedi 20 Juin 14H30. Room 718
Marijke Bryckaert: Abstract OR003: A GAIN-OF-FUNCTION MUTATION IN FILAMIN-A POTENTIATES PLATELET INTEGRIN ΑLPHA-IIB/ΒETA-3 ACTIVATION
Lundi 22 Juin 8H30. Room 718
Sophie Susen: Abstract OR024 TYPE 2N VON WILLEBRAND DISEASE: ONE VARIANT BUT MORE THAN ONE DISEASE (8:45)
Session VWD – classification, subtypes – I
Lundi 22 Juin 8H45, Room 716
Jenny Goudemand: Abstract OR025 HETEROGENEITY OF VON WILLEBRAND DISEASE TYPE 3 IN A FRENCH COHORT OF 75 PATIENTS (9 :00)
Session VWD – classification, subtypes – I
Lundi 22 Juin 9H00, Room 716
Jenny Goudemand: Abstract OR143: PLASMA-DERIVED FACTOR VIII PRODUCTS AND INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED BOYS WITH SEVERE HEMOPHILIA A : REPORT OF THE FRANCECOAG NETWORK
Session hemophilia inhibitors
Mardi 23 Juin 8h30, Room 801
Vincent Muczynski: Abstract OR246: MACROPHAGE-SPECIFIC RECEPTOR SR-AI PLAYS A CRUCIAL PROTECTIVE ROLE IN THE REGULATION OF COAGULATION FACTOR X PLASMA LEVELS.
Mardi 23 Juin 14H00. Room 709
Alexandre Kauskot: Abstract OR234: TYPE 2B VON WILLEBRAND DISEASE (VWD) IS CHARACTERIZED BY A CYTOSKELETAL DESORGANIZATION IN MEGAKARYOCYTES LEADING TO MACROTHROMBOCYTOPENIA.
Mardi 23 Juin 14H45. Room 717.
Antoine Rauch: Abstract OR219: EARLY VON WILLEBRAND FACTOR DEGRADATION UPON ACUTE EXPOSURE TO HIGH SHEAR STRESS UNDER CONTINUOUS-FLOW CIRCULATORY ASSIST DEVICES
Session Acquired disorders; Clinical II
Mardi 23 Juin, 14H45, Room 716
Frédéric Adam: Abstract OR205: CHARACTERIZATION OF A NEW GENETICALLY-ENGINEERED VON WILLEBRAND DISEASE TYPE 2B MOUSE MODEL.
Mardi 23 Juin 15H00. Room 701
Amine Bazaa: Abstract AS062: VON WILLEBRAND FACTOR IS INDISPENSABLE FOR VENOUS HEMOSTASIS IN A NOVEL MURINE BLEEDING MODEL
Mardi 23 Juin 17H15. Room 801
Caterina Casari: Abstract OR333: NEW IN VITRO AND IN VIVO STRATEGIES TO MODULATE VON WILLEBRAND FACTOR GENE MUTATIONS WITH DOMINANT-NEGATIVE EFFECT
Mercredi 24 Juin 14H30. Room 801
Antoine Rauch: Abstract AS134: ELISA-BASED ASSESSMENT OF EXCESSIVE VON WILLEBRAND FACTOR PROTEOLYSIS
Abstract Symposium: Assay challenges
Mercredi 24 Juin, 16H55, Room 709
Posters :
E Gouider: Abstract PO650-MON: EFFICACY AND SAFETY OF von WILLEBRAND FACTOR CONCENTRATE WITH A LOW FVIII CONTENT IN SEVERE VWD CHILDREN LESS THAN 6 YEARS OF AGE
Lundi 22 Juin 18H00-19H30, Section Von Willebrand disease I
François Saller: Abstract PO339-TUE: ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE PROTEOGLYCANS
Mardi 23 Juin 18H00-19H30. Section Natural Anticoagulants
Judicaël Fazavana: Abstract PO553-TUE: THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVATED FACTOR VII (FVIIA) IN COMPLEX WITH ANTITHROMBIN
Mardi 23 Juin 18H00-19H30. Section Tissue Factor and factor VII-II
Gabriel Aymé: Abstract PO658-TUE: CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLEBRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY
Mardi 23 Juin 18H00-19H30. Section Von Willebrand factor II
Paulette Legendre: Abstract PO664-TUE: FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF VON WILLEBRAND FACTOR
Mardi 23 Juin 18H00-19H30. Section Von Willebrand factor II
Antoine Rauch: Abstract PO662-TUE: VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS
Mardi 23 Juin 18H00-19H30. Section Von Willebrand factor II
Mathilde Giraud: Abstract PO645-TUE: WILLEBRAND DISEASE MOLECULE DIAGNOSIS BY HIGH THROUGHPUT SEQUENCING: WHAT’S ABOUT THE HIGLY HOMOLOGOUS PSEUDOGENE
Mardi 23 Juin 18H-19H30, Section von Willebrand disease II
Annie Borel-Derlon: Abstract PO639-TUE: HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH-ECONOMIC ASSESSMENT IN PATIENTS WITH von WILLEBRAND DISEASE IN FRANCE: THE WISH-QOL STUDY;
Mardi 23 Juin 18H-19H30, Section von Willebrand disease II
Amine Bazaa: Abstract PO206-WED: DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS
Mercredi 24 Juin 17H30-18H15. Section Coagulation factor VIII and IX – III
Ziane Elaib: Abstract PO444-WED: SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SARCO-ENDOPLASMIC RETICULUM CALCIUM ATPASE TYPE 3
Mercredi 24 Juin 17H30-18H15. Section Platelet activation/adhesion/aggregation III
All information regarding the program and registration can also be found on the Website : Shenc web site
